Abstract
Sentinel lymph node biopsy was attempted in 336 patients with clinically node-negative cutaneous melanoma. All patients were injected with technetium-99m labelled radiocolloid, with 108 patients simultaneously receiving vital blue dye for sentinel node identification. Sentinel lymph nodes were identified in 329 patients, giving a technical success rate of 97.9%. Metastatic disease was identified in 39 (11.9%) of the patients in whom sentinel nodes were found. Patients with negative sentinel nodes were observed and patients with positive sentinel nodes underwent comprehensive lymph node dissection. The presence of metastatic disease in the sentinel nodes and primary tumour depth by Breslow or Clark levels were joint predictors of survival based on Cox proportional hazards modelling. Disease recurrences occurred in 26 (8.8%) patients with negative sentinel lymph nodes, with isolated regional recurrences as the first site in 10 (3.4%). No patients with Clark level II primary tumours were found to have positive sentinel nodes or disease recurrences. One patient with a thin (<0.75mm) Clark level III primary had metastatic disease in a sentinel node. Patients with metastases confined to the sentinel nodes had similar survival rates regardless of the number of nodes involved.
| Original language | English |
|---|---|
| Pages (from-to) | 45-55 |
| Number of pages | 11 |
| Journal | Melanoma Research |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2001 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cancer Research
- Dermatology
Cite this
Gamma probe guided biopsy of the sentinel node in malignant melanoma : A multicentre study. / Harlow, S. P.; Krag, D. N.; Ashikaga, T.; Weaver, D. L.; Meijer, S. J.; Loggie, Brian W.; Tanabe, K. K.; Whitworth, P.; Kuhn, J.; Kusminsky, R.; Carp, N. Z.; Gadd, M.; Rawlings, M.; Slingluff, C. L.
In: Melanoma Research, Vol. 11, No. 1, 2001, p. 45-55.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Gamma probe guided biopsy of the sentinel node in malignant melanoma
T2 - A multicentre study
AU - Harlow, S. P.
AU - Krag, D. N.
AU - Ashikaga, T.
AU - Weaver, D. L.
AU - Meijer, S. J.
AU - Loggie, Brian W.
AU - Tanabe, K. K.
AU - Whitworth, P.
AU - Kuhn, J.
AU - Kusminsky, R.
AU - Carp, N. Z.
AU - Gadd, M.
AU - Rawlings, M.
AU - Slingluff, C. L.
PY - 2001
Y1 - 2001
N2 - Sentinel lymph node biopsy was attempted in 336 patients with clinically node-negative cutaneous melanoma. All patients were injected with technetium-99m labelled radiocolloid, with 108 patients simultaneously receiving vital blue dye for sentinel node identification. Sentinel lymph nodes were identified in 329 patients, giving a technical success rate of 97.9%. Metastatic disease was identified in 39 (11.9%) of the patients in whom sentinel nodes were found. Patients with negative sentinel nodes were observed and patients with positive sentinel nodes underwent comprehensive lymph node dissection. The presence of metastatic disease in the sentinel nodes and primary tumour depth by Breslow or Clark levels were joint predictors of survival based on Cox proportional hazards modelling. Disease recurrences occurred in 26 (8.8%) patients with negative sentinel lymph nodes, with isolated regional recurrences as the first site in 10 (3.4%). No patients with Clark level II primary tumours were found to have positive sentinel nodes or disease recurrences. One patient with a thin (<0.75mm) Clark level III primary had metastatic disease in a sentinel node. Patients with metastases confined to the sentinel nodes had similar survival rates regardless of the number of nodes involved.
AB - Sentinel lymph node biopsy was attempted in 336 patients with clinically node-negative cutaneous melanoma. All patients were injected with technetium-99m labelled radiocolloid, with 108 patients simultaneously receiving vital blue dye for sentinel node identification. Sentinel lymph nodes were identified in 329 patients, giving a technical success rate of 97.9%. Metastatic disease was identified in 39 (11.9%) of the patients in whom sentinel nodes were found. Patients with negative sentinel nodes were observed and patients with positive sentinel nodes underwent comprehensive lymph node dissection. The presence of metastatic disease in the sentinel nodes and primary tumour depth by Breslow or Clark levels were joint predictors of survival based on Cox proportional hazards modelling. Disease recurrences occurred in 26 (8.8%) patients with negative sentinel lymph nodes, with isolated regional recurrences as the first site in 10 (3.4%). No patients with Clark level II primary tumours were found to have positive sentinel nodes or disease recurrences. One patient with a thin (<0.75mm) Clark level III primary had metastatic disease in a sentinel node. Patients with metastases confined to the sentinel nodes had similar survival rates regardless of the number of nodes involved.
UR - http://www.scopus.com/inward/record.url?scp=0035134805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035134805&partnerID=8YFLogxK
U2 - 10.1097/00008390-200102000-00006
DO - 10.1097/00008390-200102000-00006
M3 - Article
VL - 11
SP - 45
EP - 55
JO - Melanoma Research
JF - Melanoma Research
SN - 0960-8931
IS - 1
ER -